120
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Use of Xpert Contributes to Accurate Diagnosis, Timely Initiation, and Rational Use of Anti-TB Treatment Among Childhood Tuberculosis Cases in South Central Ethiopia

, ORCID Icon, & ORCID Icon
Pages 153-160 | Published online: 14 May 2020

References

  • Stephen MG, Tahmeed A, Farhana A, Renee B. Evaluation of tuberculosis diagnostics in children: proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis. 2012;205(1).
  • Guillermo ES, Schmitz TL, Cama R, et al. Pulmonary tuberculosis in children in a developing country. Pediatrics. 2001;108(2). doi:10.1542/peds.108.6.1367
  • Qing QY, Wei WJ, Rui H. Rapid diagnosis of childhood pulmonary tuberculosis by Xpert MTB/RIF assay using bronchoalveolar lavage fluid. BioMed Res Int. 2014;2014:31019425165698
  • Neeraj R, Kuldeep Singh S, Sreenivas AN, et al. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLoS One. 2014;9(8):e105346.25140877
  • Durovni B, Saraceni V, van den Hof S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med. 2014;12(12):e1001928.
  • Dodd J, Gardiner E, Coghlan R, Seddon A. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modeling study. Lancet Glob Health. 2014;2:453–459. doi:10.1016/S2214-109X(14)70245-1
  • Federal Democratic Republic of Ethiopia Minister of Health. Guidelines for Clinical and Programmatic Management of TB, Leprosy and TB/HIV in Ethiopia. 6th ed. 2018.
  • World Health Organization. Global Tuberculosis Report; 2019.
  • Federal Democratic Republic of Ethiopia Minister of Health. National Population Based Tuberculosis Prevalence Survey. Ethiopia Health and Nutrition Research Institute; 2015.
  • Berti E, Galli L, Venturini E, et al. Tuberculosis in childhood: a systematic review of national and international guidelines. BMC Infect Dis. 2014;14(1):S3.
  • World Health Organization. Multidrug-Resistant Tuberculosis (MDR-TB); 2016.
  • David P, Ellen J, Fred T. The Need for Better Diagnostic Tests for Pediatric Tuberculosis. Vol. 4 2011:3–7.
  • Claude K. Paediatric Tuberculosis: Is the World Doing Enough? World’s Largest Science, Technology & Medicine. Open Access book publisher; 2013:372–380.
  • World Health Organization. Xpert MTB/RIF Implementation Manual; 2014.
  • Theron G, Peter J, van Zyl-smit R. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 2011;184(1):132–140. doi:10.1164/rccm.201101-0056OC21493734
  • Haider A, Abed A, Humaira A, Kee P, Frederick L. The diagnostic performance of a single geneXpert MTB/RIF assay in an intensified tuberculosis case. PLoS One. 2013;8(9).
  • Jain SK, Ordonez A, Kinikar A, et al. Pediatric tuberculosis in young children in India: a prospective study. Biomed Res Int. 2013;2013:783698.24386640
  • Richard J. Impact of the Xpert MTB/RIF tuberculosis diagnostic system in individuals at high risk of mortality in rural South Africa. London School Hygiene & Tropical Medicine; 2015.
  • Zeka AN, Sezai T, Cengiz C. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extra pulmonary specimens. J Clin Microbiol. 2011;49(12):4138–4141. doi:10.1128/JCM.05434-1121956978
  • Do C, Tran Ngoc D, Dang T, Ho T, Marcel W. Prospective evaluation of GeneXpert for the diagnosis of HIV-negative pediatric TB cases. BMC Infect Dis. 2015;15(70).
  • Davis JL, Masae Kawamura L, Chaisson LH, Jennifer G. Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. Am J Respir Crit Care Med. 2014;189(12):1551–1559. doi:10.1164/rccm.201311-1974OC24869625
  • Evans CA. Gene Xpert-A game changer for Tuberculosis control. PLoS Med. 2011;8(7):e1001064. doi:10.1371/journal.pmed.100106421814497
  • Menzies NA, Ted C. Population health impact and cost effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: dynamic simulation and economic evaluation. PLoS Med. 2012;9(11). doi:10.1371/journal.pmed.1001347
  • Catharina C, Mark B, Pamela N, Joy M. Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the Xpert MTB/RIF test for the diagnosis of tuberculosis and multi drug resistance: a multi-center implementation study. Lancet. 2011;377:1495–1505. doi:10.1016/S0140-6736(11)60438-821507477
  • Gesine M, Kathryn S, Lawrence L, William M. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2015;7(5):e36966.
  • Laura M, Natasha L, Jurgens AP, Stephen D. Diagnostic accuracy of the Xpert MTB/RIF assay for extra pulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infect Dis. 2014;14(709).
  • Habte D, Melese M, Hiruy N, Gashu Z. The additional yield of GeneXpert MTB/RIF test in the diagnosis of pulmonary tuberculosis among household contacts of smear positive TB cases. Int J Infect Dis. 2016;49:179–184. doi:10.1016/j.ijid.2016.07.00227401584
  • Grant T, Jonny P, Greg C, Richard M. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep. 2014;4: 5658.25014250
  • Monika A, ShiSh B, Vinay B. Comparative study of GeneXpert with ZN stain and culture in samples of suspected pulmonary tuberculosis. J Clin Diagn Res. 2016;10(5):DC09–12.
  • Jenkins HE. Global burden of childhood tuberculosis. BMC Jenkins Pneumonia. 2016;8(1):24.